NF1 and glioblastoma: While the updated 2021 WHO Classification of Tumors of the Central Nervous System incorporates an ever-increasing number of molecular criteria for diffuse astrocytic tumors (10), the existence and clinical importance of heterogeneity between and within somatic NF1-mutant, isocitrate dehydrogenase (IDH) wild-type glioblastomas remain unclear.